Zai Lab Signs an Exclusive License Agreement with Cullinan Oncology for the Development and Commercialization of CLN-081 in Greater China

Shots:

  • Cullinan will receive $20M up front and is eligible to receive ~$211M in development, regulatory and sales-based milestone payments
  • Cullinan is also eligible for high-single-digit to low-teen tiered royalties based on sales of CLN-081 in Greater China includes Hong Kong, Macau and Taiwan
  • CLN-081 is an orally available, small-molecule, irreversible EGFR inhibitor, which is currently in P-I/IIa dose escalation and expansion trial for NSCLC patients

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Business Wire

The post Zai Lab Signs an Exclusive License Agreement with Cullinan Oncology for the Development and Commercialization of CLN-081 in Greater China first appeared on PharmaShots.

ImmunoGen Signs an Agreement with Huadong to Develop & Commercialize Mirvetuximab Soravtansine in Greater China

Shots:

  • ImmunoGen to receive $40M up front, ~$265M as development, regulatory & commercial milestones and is eligible to receive royalties on sales of mirvetuximab in Greater China and will retain all rights to mirvetuximab in the US & ROW
  • The collaboration accelerates the development path for mirvetuximab in Greater China and expands Huadong’s oncology portfolio with innovative ADC and combines ImmunoGen’s lead clinical program with Huadong’s regional oncology expertise
  • Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a FRα binding antibody, cleavable linker & the maytansinoid DM4 to kill the targeted cancer cells

Click here ­to­ read full press release/ article | Ref: ImmunoGen | Image: PNGitem

The post ImmunoGen Signs an Agreement with Huadong to Develop & Commercialize Mirvetuximab Soravtansine in Greater China first appeared on PharmaShots.